Shopping Cart
- Remove All
Your shopping cart is currently empty
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $169 | In Stock | |
| 5 mg | $448 | In Stock | |
| 10 mg | $715 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,460 | In Stock |
| Description | Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases. |
| In vitro | Methods: Isolated intrinsic monocyte layer (LPMC) and mucosal tissue explants were incubated with Otelixizumab for 24-48 hours. The production of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. Results: Incubation of LPMC with Otelixizumab reduced the production of interferon gamma, interleukin (IL) -17A, and other inflammatory cytokines and chemokines, while increasing the production of IL-10.[1] |
| In vivo | Human CD3ε chain (nod-HUCdε) transgenic mice treated with Otelixizumab (50 μg/ day, 5 days, intravenously) experienced remission of diabetes symptoms in 47% of mice.[2] |
| Synonyms | TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3 |
| Cas No. | 881191-44-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.